Global Paromomycin (CAS 75432) Market is expected to grow at a CAGR of XX% during the forecast period. The major factors driving the growth of this market are increasing prevalence of bacterial infections, growing geriatric population, and rising demand for antimicrobial agents.
The global Paromomycin (CAS 75432) market is segmented on the basis of type, application and region. On the basis of type, it is divided into 95% purity type and 96% purity type. On the basis of application, it is divided into paromomycin sulfate and paromomycin injection. On the basis of region, it is divided into North America, Latin America, Europe, Asia Pacific and Middle East & Africa regions.
Some Of The Growth Factors Of This Market:
- Paromomycin is a potent antibiotic that is used to treat infections caused by susceptible strains of bacteria.
- It has been approved for use in the United States since 1959 and is available as an oral suspension or tablet, and intravenous injection.
- The drug has been shown to be effective against a wide range of bacterial infections, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, septicemia (blood poisoning), meningitis (inflammation of the membranes surrounding the brain), gonorrhea (a sexually transmitted disease) and chlamydia (a sexually transmitted disease).
- Paromomycin can also be used to treat certain types of malaria caused by Plasmodium falciparum.
- The drug works by interfering with protein synthesis in bacteria.
Industry Growth Insights published a new data on “Paromomycin (CAS 7542-37-2) Market”. The research report is titled “Paromomycin (CAS 7542-37-2) Market research by Types (95% Purity Type, 96% Purity Type, Others), By Applications (Paromomycin Sulfate, Paromomycin Injection), By Players/Companies Pfizer, Kaifeng Pharm, Shanhe Pharm, Changrui Pharm, ERFA Canada”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Paromomycin (CAS 7542-37-2) Market Research Report
By Type
95% Purity Type, 96% Purity Type, Others
By Application
Paromomycin Sulfate, Paromomycin Injection
By Companies
Pfizer, Kaifeng Pharm, Shanhe Pharm, Changrui Pharm, ERFA Canada
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global Paromomycin (CAS 7542-37-2) Market Report Segments:
The global Paromomycin (CAS 7542-37-2) market is segmented on the basis of:
Types
95% Purity Type, 96% Purity Type, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Paromomycin Sulfate, Paromomycin Injection
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Kaifeng Pharm
- Shanhe Pharm
- Changrui Pharm
- ERFA Canada
 Market Overview.svg)
Highlights of The Paromomycin (CAS 7542-37-2) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 95% Purity Type
- 96% Purity Type
- Others
- By Application:
- Paromomycin Sulfate
- Paromomycin Injection
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Paromomycin (CAS 7542-37-2) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Paromomycin is a macrolide antibiotic. It is used to treat infections caused by certain types of bacteria, including Streptococcus pneumoniae and Staphylococcus aureus. Paromomycin may also be used to prevent or treat other infections.
Some of the major companies in the paromomycin (cas 7542-37-2) market are Pfizer, Kaifeng Pharm, Shanhe Pharm, Changrui Pharm, ERFA Canada.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Paromomycin (CAS 7542-37-2) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Paromomycin (CAS 7542-37-2) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Paromomycin (CAS 7542-37-2) Market - Supply Chain
4.5. Global Paromomycin (CAS 7542-37-2) Market Forecast
4.5.1. Paromomycin (CAS 7542-37-2) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Paromomycin (CAS 7542-37-2) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Paromomycin (CAS 7542-37-2) Market Absolute $ Opportunity
5. Global Paromomycin (CAS 7542-37-2) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Type
5.3.1. 95% Purity Type
5.3.2. 96% Purity Type
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Paromomycin (CAS 7542-37-2) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Application
6.3.1. Paromomycin Sulfate
6.3.2. Paromomycin Injection
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Paromomycin (CAS 7542-37-2) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Paromomycin (CAS 7542-37-2) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Paromomycin (CAS 7542-37-2) Demand Share Forecast, 2019-2026
9. North America Paromomycin (CAS 7542-37-2) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Application
9.4.1. Paromomycin Sulfate
9.4.2. Paromomycin Injection
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Type
9.7.1. 95% Purity Type
9.7.2. 96% Purity Type
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Paromomycin (CAS 7542-37-2) Demand Share Forecast, 2019-2026
10. Latin America Paromomycin (CAS 7542-37-2) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Application
10.4.1. Paromomycin Sulfate
10.4.2. Paromomycin Injection
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Type
10.7.1. 95% Purity Type
10.7.2. 96% Purity Type
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Paromomycin (CAS 7542-37-2) Demand Share Forecast, 2019-2026
11. Europe Paromomycin (CAS 7542-37-2) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Application
11.4.1. Paromomycin Sulfate
11.4.2. Paromomycin Injection
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Type
11.7.1. 95% Purity Type
11.7.2. 96% Purity Type
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Paromomycin (CAS 7542-37-2) Demand Share, 2019-2026
12. Asia Pacific Paromomycin (CAS 7542-37-2) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Application
12.4.1. Paromomycin Sulfate
12.4.2. Paromomycin Injection
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Type
12.7.1. 95% Purity Type
12.7.2. 96% Purity Type
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Paromomycin (CAS 7542-37-2) Demand Share, 2019-2026
13. Middle East & Africa Paromomycin (CAS 7542-37-2) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Application
13.4.1. Paromomycin Sulfate
13.4.2. Paromomycin Injection
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Paromomycin (CAS 7542-37-2) Market Size and Volume Forecast by Type
13.7.1. 95% Purity Type
13.7.2. 96% Purity Type
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Paromomycin (CAS 7542-37-2) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Paromomycin (CAS 7542-37-2) Market: Market Share Analysis
14.2. Paromomycin (CAS 7542-37-2) Distributors and Customers
14.3. Paromomycin (CAS 7542-37-2) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Kaifeng Pharm
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Shanhe Pharm
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Changrui Pharm
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ERFA Canada
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
